Eli Lilly Makes a $3.8 Billion Bet on Psychedelic Medicine
Eli Lilly has agreed to acquire clinical-stage biotechnology company AtaiBeckley in a transaction worth approximately $2.8 billion upfront and as much as $3.8 billion if specified development and regulatory milestones are achieved. The agreement moves…